Suzanne Kamel-Reid

发表

Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale.

Helen E White, Dong-Wook Kim, Timothy Hughes, 2013, Clinical chemistry.

Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

Marina N Nikiforova, John Pfeifer, Karl V Voelkerding, 2017, The Journal of molecular diagnostics : JMD.

A gene signature in histologically normal surgical margins is predictive of oral carcinoma recurrence

Igor Jurisica, Levi Waldron, Melania Pintilie, 2011, BMC Cancer.

Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations.

Suzanne Kamel-Reid, S. Kamel‐Reid, Tong Zhang, 2007, The Journal of molecular diagnostics : JMD.

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

Suzanne Kamel-Reid, Peter Forsyth, W. Mason, 2009, Cancer Chemotherapy and Pharmacology.

Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma.

Marina N Nikiforova, Suzanne Kamel-Reid, M. Nikiforova, 2012, Archives of pathology & laboratory medicine.

Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing

Annette S. Kim, Neal I. Lindeman, David L. Rimm, 2017, JAMA oncology.

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer

Celeste Yu, Lisa Wang, Suzanne Kamel-Reid, 2017, Breast Cancer Research and Treatment.

Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics.

Swati Garg, Suzanne Kamel-Reid, S. Kamel‐Reid, 2016, The Journal of molecular diagnostics : JMD.

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

Suzanne Kamel-Reid, Peter Emanuel, J. Radich, 2012, Blood.

Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Lesley Seymour, Ming-Sound Tsao, Suzanne Kamel-Reid, 2005, The New England journal of medicine.

Equivocal p16 Immunostaining in Squamous Cell Carcinoma of the Head and Neck: Staining Patterns are Suggestive of HPV Status

Suzanne Kamel-Reid, S. Kamel‐Reid, B. Perez-Ordonez, 2012, Head and Neck Pathology.

Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease.

Suzanne Kamel-Reid, Lawrence J Jennings, S. Kamel‐Reid, 2012, Archives of pathology & laboratory medicine.

Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss.

John Doyle, Fred Saunders, Lillian Sung, 2002, Blood.

A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer

Suzanne Kamel-Reid, S. Kamel‐Reid, Philippe Bédard, 2015, Genetics in Medicine.

Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial

Vincent Ferretti, John D McPherson, Ben Tran, 2013, International journal of cancer.

Clinical genomics information management software linking cancer genome sequence and clinical decisions.

Vincent Ferretti, John D McPherson, Ben Tran, 2013, Genomics.

Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays.

Rakesh Nagarajan, Stephen B Montgomery, Annette S. Kim, 2018, Archives of pathology & laboratory medicine.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Paul Metcalfe, Helen E White, Susan Branford, 2010, Blood.

Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma.

Igor Jurisica, Bekim Sadikovic, Melania Pintilie, 2009, Human molecular genetics.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Simona Soverini, Giovanni Martinelli, Susan Branford, 2006, Blood.

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

Lesley Seymour, Ming-Sound Tsao, Suzanne Kamel-Reid, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

Carl Virtanen, Mahadeo A. Sukhai, Trevor J. Pugh, 2016, Genome Medicine.